NovelStem International

NSTM

Medical - Diagnostics & Research · Healthcare

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

NovelStem International Corp. is a small healthcare company focused on stem cell research and related biotechnology. The company works in the field of regenerative medicine, which involves using stem cells to potentially treat diseases or repair damaged tissue. It operates in the medical research and diagnostics industry, targeting scientific and clinical markets.

NovelStem generates little to no revenue at this stage, reflecting its early-stage status as a development-phase company. It has no meaningful gross margin or operating income, and its deeply negative return on invested capital signals that it is spending far more than it earns. The company's main risk is its ability to raise enough capital to continue operations and advance any research programs toward commercialization, which is a common and serious challenge for micro-cap biotech firms with no established product revenue.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

-10%

Weak — only -10% of profit becomes cash

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

0.2x

no trend

Attractive valuation — P/E 0.2

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial